70 Chapter 4 Endothelial and coagulant response 10 100 sE−selectin (ng/mL) sE−selectin ** 1 10 sVCAM−1 (µ/mL) sVCAM1 ** 1 10 Syndecan (ng/mL) Syndecan 1 10 Endocan (ng/mL) Endocan ** 10 100 Tie−2 (ng/mL) Tie−2 1 10 100 Angiopoietin−1 (ng/mL) Angiopoietin−1 * 1 10 100 Angiopoietin−2 (ng/mL) Angiopoietin−2 * 0.1 1 vWF (ng/mL) vWF 0 1 10 ADAMTS13 (mg/mL) ADAMTS13 * 0 10 Thrombomodulin (ng/mL) Thrombomodulin ** 10 100 1,000 Protein−C (ng/mL) Protein−C * 10 100 TFPI (ng/mL) TFPI * 1 10 100 1,000 10,000 D−Dimer (ng/mL) D−Dimer Median control subjects Group Ferritin <500 ng/ml Ferritin ≥500 ng/ml Figure 4. Endothelial and coagulant responses of patients with CAP stratified according to a plasma ferritin concentration of <500 ng/ml or ≥500 ng/ml. Patients were stratified into those with plasma ferritin <500 ng/ml (n = 128) or ≥500 ng/ml (n = 46). Data are expressed as box-andwhisker diagrams with the horizontal line depicting the median, the top and bottom of the box representing the lower and upper quartiles, and whiskers extending to the farthest points that are not outliers (i.e., that are within 1.5 times the interquartile range of the lowest and the highest quartile, respectively). Dotted lines represent median values obtained in 50 age- and sex matched controls. Asterisks indicate differences between groups (Benjamini-Hochberg corrected, *p <0.05, **p <0.01). s = soluble; sVCAM = soluble vascular cell adhesion molecule; vWF = von Willebrand factor; ADAMTS13 = a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; TFPI = tissue factor pathway inhibitor.
RkJQdWJsaXNoZXIy MTk4NDMw